Press Releases

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

Amyris Announces Launch of Secondary Offering by Certain Selling Stockholders

EMERYVILLE, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) (“Amyris” or the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that certain of its existing stockholders (the “selling stockholders”) intend to offer up to approximately 7.4 million shares of the Company’s common stock in an underwritten secondary offering. In addition, one of the selling stockholders intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered in the secondary offering.

In connection with the offering, the selling stockholders shall exercise approximately 10.5 million warrants, which is expected to result in net cash proceeds to Amyris of approximately $46 million. 

The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of shares in the offering. The selling stockholders will receive all of the net proceeds from the offering.

B. Riley FBR, Inc. is acting as underwriter for the offering. The offering is being made pursuant to two effective registration statements on Form S-3 previously filed by the Company with the Securities and Exchange Commission (“SEC”). The offering is being made only by means of two prospectuses and related prospectus supplements, copies of which may be obtained on the website of the SEC, www.sec.gov., or from B. Riley FBR, Inc., Attn: Syndicate Prospectus Department, 1300 North 17th Street, Suite 1400, Arlington, VA 22209; Phone: (703) 312-9580; Email: prospectuses@brileyfbr.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About B. Riley FBR, Inc.
B. Riley FBR, Inc. is a leading investment bank which provides corporate finance, research and sales and trading to corporate, institutional and high net worth individual clients. Investment banking services include initial, secondary and follow-on offerings, institutional private placements and merger and acquisitions advisory services, and corporate restructuring. The firm is nationally recognized for its highly ranked proprietary equity research. B. Riley FBR is a wholly-owned subsidiary of B. Riley Financial, Inc. (NASDAQ: RILY), a diversified provider of financial and business advisory services. To learn more about B. Riley FBR, visit www.brileyfbr.com.

About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the exercise of existing warrants and the receipt of the applicable exercise prices by Amyris in connection therewith), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc. 
+1 (510) 740-7481
investor@amyris.com

Contact Us

For media inquiries, please contact: info@amyris.com
For investor inquiries, please contact: investor@amyris.com